Form 4: Cadrenal Therapeutics CFO Matthew Szot Acquires 50,000 Stock Options

Cadrenal Therapeutics' Chief Financial Officer, Matthew Szot, was granted 50,000 stock options on January 23, 2025.

Summary

• Matthew Szot, the Chief Financial Officer of Cadrenal Therapeutics, Inc., was granted 50,000 stock options on January 23, 2025.
• These options have an exercise price equal to the fair market value of the company's common stock on the grant date.
• The options vest over a period of three years, with 25% vesting on February 1, 2026, and the remainder vesting monthly thereafter, contingent on continued service.
• The options expire on January 22, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of Cadrenal Therapeutics' stock price.
• If the CFO leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next three years, incentivizing the CFO to contribute to the company's long-term success.

Industry Context

Stock option grants are a common form of compensation for executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotechnology industry, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule of three years with a cliff vest at 25% followed by monthly vesting is also a common practice in the industry.
• The exercise price being set at the fair market value on the grant date is standard practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Cadrenal Therapeutics, Matthew Szot, CFO, equity compensation, vesting